GEN Exclusives

More »

Insight & Intelligence™

Back to Item »

With Oligonucleotide Drugs, Antisense Arrives but RNAi Has a Long Way to Go

Isis filed an NDA for its HoFH antisense treatment, while Alnylam reported Phase III failure with RSV infection RNAi candidate.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Why Some People Are Anti-GMO?

Do you think GMOs would be viewed more favorably if more attention was paid to the resulting product rather than the GMO technology used to produce it?

More »